SLS · NASDAQ · STOCK
SELLAS Life Sciences Group, Inc.
$11.03
52W $1.39 – $15.88
57/100
$2.06B
-52.3
2.49
Is SLS Bullish or Bearish?
Mixed.
Innellis AI committee rates SELLAS Life Sciences Group, Inc. (SLS) Watch with a composite score of 57/100
, based on 5 analysts with 80% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +3.17 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -16.83 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- Beta of 2.54 means this name should amplify a favorable market regime — Macro
Bear Case
- Price-to-book of 7.6x prices in significant intangible value — Value
- ROE of only -47.1% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 33.5% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
57/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 71%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 7.6x prices in significant intangible value
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 33.5% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
43.9
Neutral
MACD Histogram
-0.083
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$3.96
Resistance
$15.86
Bollinger %B
0.37
Inside Bands
Price vs Moving Averages
EMA 9
$11.32
Below
EMA 21
$11.43
Below
EMA 50
$10.65
Above
EMA 200
$6.78
Above
Fundamental Analysis
Valuation
67
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-52.3×
P/B Ratio
15.19×
PEG Ratio
-1.13
Dividend Yield
0.00%
52W High
$15.88
52W Low
$1.39
Quality & Growth
ROE
-3790.4%
ROA
-3428.8%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -52.3 (inexpensive relative to a 15-40x range); Price-to-book of 15.2x; PEG ratio of -1.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -37.9%; Return on assets of -34.3%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 18.83 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is negative (-0.15); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full SLS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →